OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
January 10, 2008
Pfizer and Hikal signed a contract manufacturing agreement in which Hikal will supply active pharmaceutical ingredients.
Crucell and Sanofi Pasteur Sign Agreement, WuXi Pharma Names COO, More...
January 09, 2008
Richard Spoor, senior vice-president of global procurement at Merck & Co., Inc., discusses the company's strategy and progress made in its supply strategy that involves increased outsourcing and implementing lean-manufacturing principles in its manufacturing network. Pharmaceutical Technology's senior editor Patricia Van Arnum moderates.
January 04, 2008
Merck Sells Facility to Cherokee Pharmaceuticals, Inflazyme Announces Senior Management Resignations, More...
January 02, 2008
The $6.3 billion Indian pharmaceutical industry is at a crossroad. Aiming to be the international home for quality drugs, which could in itself propel India's market to $20 billion by 2015 according to recent estimates, the generic hothouse is clearly moving beyond its earlier low-cost mindset.
The outsourcing of clinical-trial materials grows as pharmaceutical companies adapt to a changing market.
What should contractors and their clients bear in mind when they collaborate on a project?
The traditional pharmaceutical business model is disintegrating, but the new model is not much different.
News, world briefs, facility roundup, events and other items for January 2008.
January 01, 2008
How much do you know about parallel trade? Perhaps you may have heard someone mention these words and have then switched off. In a sense, it's hardly surprising given the fact that most media coverage centres on interpretation of complex legal cases. By the time you reach the end of these types of articles, you can't work out what the mentioned companies were arguing about in the first place and on which technical details the case was judged. Yet, time after time, a legal ruling on a parallel trade issue rockets to the front pages of the pharmaceutical press and even, occasionally, the mainstream media.